MedPath

Electroconvulsive therapy versus ketamine for improving symptoms in treatment resistant depressio

Not Applicable
Conditions
Health Condition 1: F332- Major depressive disorder, recurrent severe without psychotic features
Registration Number
CTRI/2020/01/022914
Lead Sponsor
All India Institute of Medical Sciences New Delhi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Age 18-65 years

2.Willing to give informed consent

3.Ability to read Hindi or English language

4.Fulfilling criteria of major depressive disorder as per Diagnostic and Statistical Manual 5 (DSM 5) in group 1 & 2

5.Treatment resistance will be defined as the failure to respond to 2 adequate trials of different classes of antidepressant medications (Sackeim, 2001)

6.Patients referred for MECT (for all study patients, a clinical decision to pursue neuromodulation would have already been made. Clinical treatment will be performed independently of this study).

Exclusion Criteria

1.Patients with chronic neurological or other physical illness

2.Suffering from any other psychiatric disorder other than major depressive disorder in their respective groups, as assessed by Mini International Neuropsychiatric Interview (MINI) screen

3.Persistent mood disorders (dysthymia) and other and unspecified depressions based on DSM 5

4.History of significant head trauma

5.Patients with alcohol or other substance abuse (except nicotine and caffeine)

6.Any history of seizure

7.Previous history of receiving any surgical procedures or electrical or magnetic stimulation on brain

8.Known or suspected pregnancy or lactating females

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes in scores of Hamilton Depression Rating Scale (HDRS)Timepoint: After first session and after 3 weeks
Secondary Outcome Measures
NameTimeMethod
Changes in activation and connectivity seen on fNIRS & QEEG during resting state as well as activation state (in response to emotional tasks) scans and changes in BDNF levelsTimepoint: After first session and after 3 weeks
© Copyright 2025. All Rights Reserved by MedPath